

Brihad Abhyankar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11364889/publications.pdf>

Version: 2024-02-01

9
papers

1,795
citations

1307594

7
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

1836
citing authors

#	ARTICLE	IF	CITATIONS
1	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2019, 381, 1215-1226.	27.0	457
2	Long-term Efficacy of Vedolizumab for Crohn's Disease. Journal of Crohn's and Colitis, 2017, 11, jjw176.	1.3	141
3	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, jjw177.	1.3	140
4	Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. Advances in Therapy, 2017, 34, 542-559.	2.9	72
5	The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 2017, 66, 839-851.	12.1	630
6	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clinical Gastroenterology and Hepatology, 2017, 15, 229-239.e5.	4.4	164
7	An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. Journal of Crohn's and Colitis, 2016, 10, 1437-1444.	1.3	184
8	Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated With Vedolizumab During the GEMINI 1 Trial. American Journal of Gastroenterology, 2015, 110, S790.	0.4	3
9	Sa1123 Infusion-Related Reactions With Vedolizumab Treatment in Patients With UC or CD During the GEMINI 1 and GEMINI 2 Clinical Trials. Gastroenterology, 2015, 148, S-232-S-233.	1.3	4